Alkahest, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2014-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.alkahest.com
A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Alkahest, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT05038020
- Locations
- 🇺🇸
Site 123, Glendale, California, United States
🇺🇸Site 118, Winter Haven, Florida, United States
🇺🇸Site 121, Huntington Beach, California, United States
Study to Compare Safety and Tolerability of AKST1210 Column at 2 Blood Flow Rates in Subjects With ESRD on Hemodialysis
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Alkahest, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04985383
- Locations
- 🇺🇸
Valley Renal Medical Group Research, Northridge, California, United States
🇺🇸US Renal Care, Gallup, New Mexico, United States
🇺🇸Renal Consultant Medical Group, Granada Hills, California, United States
A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment
- Conditions
- Interventions
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Alkahest, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04527328
- Locations
- 🇺🇸
Renal Consultants Medical Group, Granada Hills, California, United States
🇺🇸US Renal Care Kidney Research, San Antonio, Texas, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid
- Conditions
- Interventions
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Alkahest, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04499235
- Locations
- 🇩🇪
Universitätsklinikum Freiburg Klinik für Dermatologie und Venerologie, Freiburg, Germany
🇩🇪Universitätsklinikum Carl Gustav Carus Dresden Klinik und Poliklinik für Dermatologie, Dresden, Germany
🇩🇪Universitätsmedizin der Johannes Gutenberg-Universität Mainz Hautklinik Clinical Research Center (CRC), Mainz, Germany
Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Alkahest, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT04369430
- Locations
- 🇩🇪
Paracelsus-Elena-Klinik Kassel, Kassel, Germany
🇩🇪Universitätsklinikum Ulm, Ulm, Germany
🇵🇱Centrum Medyczne PRATIA/ Medical Center PRATIA, Częstochowa, Poland
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD
- Conditions
- Interventions
- First Posted Date
- 2020-04-02
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Alkahest, Inc.
- Target Recruit Count
- 107
- Registration Number
- NCT04331730
- Locations
- 🇩🇪
nordBLICK Augenklinik Bellevue, Kiel, Germany
🇺🇸Sierra Eye Associates, Reno, Nevada, United States
🇩🇪Internationale Innovative Ophthalmochirurgie GbR, Düsseldorf, Germany
A Study to Evaluate the Effect of GRF6021 on Postoperative Recovery Following Primary Hip or Knee Arthroplasty
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Alkahest, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT03981419
- Locations
- 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Alkahest, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT03765762
- Locations
- 🇺🇸
Cognitive Clinical Trials, Phoenix, Arizona, United States
🇺🇸Pacific Research Network, San Diego, California, United States
🇺🇸Riverside Clinical Research, Edgewater, Florida, United States
A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Alkahest, Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT03713957
- Locations
- 🇺🇸
NeuroTrials Research Inc., Atlanta, Georgia, United States
🇺🇸Clinical Trials, Inc., Little Rock, Arkansas, United States
🇺🇸Rocky Mountain Movement Disorders Center, Englewood, Colorado, United States
Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Alkahest, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT03558074
- Locations
- 🇭🇺
Jahn Ferenc South-Pest Hospital and Clinic, Budapest, Hungary
🇭🇺Markusovszky University Teaching Hospital, Szombathely, Hungary
🇭🇺Borsod-Abauj-Zemplen County Hospital and Teaching Hospital, Miskolc, Hungary